Maxcyte Inc Feed

2026-09-11 22:30:00 MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-19 14:05:00 MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

2026-07-21 14:05:00 MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development

2026-07-15 22:05:00 MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026

2026-04-29 22:05:00 MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

2026-03-24 21:05:00 MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

2026-03-23 13:05:00 MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

2026-02-24 14:05:00 MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

2026-02-23 22:05:00 MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

2026-01-12 14:05:00 MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

2025-11-12 22:08:00 MaxCyte Announces Planned CFO Transition in 2026

2025-11-12 22:05:00 MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

2025-11-05 14:05:00 MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

2025-10-08 14:05:00 MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025

2025-10-06 14:05:00 MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors

2025-09-22 22:30:48 MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability

2025-08-04 14:05:00 MaxCyte Signs Platform License Agreement with Adicet Bio

2025-07-31 14:05:00 MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline

2025-07-09 14:05:00 MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025

2025-06-11 08:00:00 MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies 168,50 GBP | -2,03%

2025-05-07 22:05:00 MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance 203,00 GBP | 0,00%

2025-04-10 08:00:00 MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025 192,00 GBP | +4,92%

2025-03-11 21:05:00 MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance 265,00 GBP | +0,38%

2025-02-12 08:00:00 MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs 332,00 GBP | -2,35%

2025-02-07 08:00:00 MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference 359,00 GBP | 0,00%

2025-01-30 08:00:00 MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments 377,00 GBP | +0,53%

2025-01-13 09:05:00 MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results 368,00 GBP | +4,84%

2024-12-23 08:00:00 MaxCyte Announces Retirement of Board Member Art Mandell 327,00 GBP | -0,91%

2024-12-09 08:00:00 MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance 315,00 GBP | +12,90%

2024-11-13 14:05:00 MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics 270,00 GBP | -1,82%

2024-11-06 22:05:00 MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance 303,00 GBP | +4,84%

2024-10-31 13:05:00 MaxCyte to Participate in Two Upcoming Investor Conferences 279,00 GBP | +1,45%

2024-10-15 14:05:00 MaxCyte Appoints Cynthia Collins to its Board of Directors 292,00 GBP | -1,02%

2024-10-11 14:05:00 MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 285,00 GBP | -2,06%

2024-10-10 14:05:00 MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer 291,00 GBP | +2,83%

2024-09-16 08:00:00 MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases 311,00 GBP | +3,67%

2024-09-05 22:05:00 MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference 304,00 GBP | -5,00%

2024-08-06 22:05:00 MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance 335,00 GBP | +2,13%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode